At a glance
| Chemical family | Paraben — propyl ester of 4-hydroxybenzoic acid; longer-chain paraben (C3 alkyl) with stronger in vitro estrogenic activity than methyl (C1) or ethyl (C2) parabens |
| CAS number | 94-13-3; E216 (EU food-additive labeling, no longer used in EU food since 2006) |
| Classification | Not formally evaluated by IARC; EU SCCS Opinions (2010, 2011, 2013) led to the propyl/butyl restrictions; EU Cosmetics Regulation 1223/2009 Annex V entry 12a permits propylparaben at 0.14% individual concentration; Commission Regulation 358/2014 banned propylparaben in EU leave-on cosmetic products for the nappy area of children under 3 (in effect since April 2015); US FDA permits under broader cosmetic regulation framework without specific concentration limits |
| Where you encounter it | Cosmetics and personal care products formulated before the 2014-2015 EU implementation; declining presence in global brand portfolios as harmonization spreads; some shampoos, conditioners, lotions, sunscreens, body washes in current US market; pharmaceutical formulations including some topical medications; historically a food preservative (E216, EU-banned 2006) |
| Sleep micro environment relevance | Same indirect pathway as methylparaben — leave-on products transfer to bedding via sweat and skin contact over the sleep window. Cumulative across the multiple paraben-containing products in a routine, with propylparaben specifically carrying disproportionate concern per molecule because of the elevated estrogenic potency |
| Activated carbon capture | Limited applicability for VOC-phase capture. Parabens are dermal-absorption and product-residue contact exposure pathways, not vapor-phase. The primary residential intervention is product-choice level. Inferred from established paraben exposure pathways |
What it is
Propylparaben — CAS 94-13-3, chemical name propyl 4-hydroxybenzoate — is the propyl ester of 4-hydroxybenzoic acid (parahydroxybenzoic acid), structurally identical to methylparaben except for the alcohol used in the ester. Methylparaben uses methanol (C1 alkyl); ethylparaben uses ethanol (C2); propylparaben uses 1-propanol (C3); butylparaben uses 1-butanol (C4). The chain-length progression is the underlying chemistry that drives the regulatory tiering: longer alkyl chains increase lipophilicity, slow hydrolysis kinetics, and — most importantly for the regulatory framework — increase in vitro estrogen receptor binding affinity.
Routledge, Parker, Odum, Ashby and Sumpter 1998 in Toxicology and Applied Pharmacology established the chain-length-versus-estrogenicity relationship across the paraben family in their foundational in vitro work, demonstrating that estrogenic activity increases progressively from methyl through butyl paraben — with propylparaben approximately 10× stronger than methylparaben in the standard yeast estrogen screen assay. Peer-reviewed Subsequent receptor binding and reporter-gene assays have largely confirmed the ranking. The absolute estrogenic activity remains low — propylparaben is still approximately three orders of magnitude weaker than 17β-estradiol — but the within-family chain-length effect is the basis for differential regulatory treatment.
Propylparaben was historically used as a food preservative under the E216 designation in the EU, but the European Food Safety Authority concluded in 2004 that the available data did not support a tolerable daily intake covering propylparaben (and the longer parabens), based on developmental and reproductive concerns in animal studies. The EU food ban took effect in 2006, predating the cosmetics restrictions by nearly a decade. The current EU food preservative parabens are limited to methylparaben (E218) and ethylparaben (E214).
Where you encounter it
From cosmetics and personal care products
The dominant residual exposure category. Lotions, sunscreens, shampoos, conditioners, body washes, and many cosmetic products formulated before the 2014-2015 EU implementation contained propylparaben as standard preservation chemistry. Post-2014 EU regulations and the harmonizing pressure on global brand portfolios have driven substantial reformulation, but propylparaben still appears on many current US-market product ingredient labels. Imported products that don't meet EU labeling may carry higher propylparaben concentrations than EU-domestic equivalents.
From the historical food preservative use (E216)
The EU food ban took effect in 2006, eliminating propylparaben from EU food applications. The US has permitted limited paraben use in food under FDA regulation. The dietary contribution to total propylparaben exposure in current US populations is small compared to the cosmetic contribution, but is documented in biomonitoring data showing propylparaben metabolites in essentially all US adults sampled by CDC NHANES.
From pharmaceutical formulations
Some topical pharmaceutical formulations (creams, ointments, lotions) contain propylparaben as a preservative, including some prescription and over-the-counter dermatological products. The pharmaceutical use case generally carries higher regulatory scrutiny than the cosmetic use, and pharmaceutical product information typically discloses propylparaben presence in the formulation.
From biomonitoring data — population-scale exposure
CDC NHANES paraben biomonitoring detects propylparaben metabolites in essentially all US adults sampled, though at lower concentrations than methylparaben metabolites reflecting the lower use rate of propylparaben in the broader product market. Regulatory Higher concentrations are seen in women than men on average, consistent with the higher cosmetic-product use pattern observed for all parabens in biomonitoring data.
What the research says
The Darbre 2004 finding — propylparaben specifically
Darbre, Aljarrah, Miller, Coldham, Sauer and Pope 2004 in Journal of Applied Toxicology measured paraben concentrations in 20 human breast tumor samples, detecting intact parabens at mean total concentrations around 20 ng/g tissue. Peer-reviewed Of the parabens detected, propylparaben showed the highest mean tissue concentration in some sample subsets — a notable finding given the lower population-level cosmetic use rate of propylparaben relative to methylparaben. The 2004 study did not establish causality but did surface the propylparaben-specific accumulation pattern that informed subsequent regulatory attention.
Endocrine activity and reproductive endpoints
The Routledge 1998 in vitro work established the increasing estrogenicity with chain length. Boberg, Taxvig, Christiansen and Hass 2010 in Reproductive Toxicology reviewed the paraben endocrine disruption literature with particular attention to the longer-chain parabens, documenting reproductive and developmental effects in animal studies at higher dose levels and the elevated regulatory concern that drove the EU restrictions. Peer-reviewed The dose levels at which animal effects appear are substantially higher than typical residential cosmetic exposure; the regulatory framework uses standard uncertainty factors to convert animal NOAEL values to residential safety concentrations.
The EU regulatory split — 2010-2014
The EU Scientific Committee on Consumer Safety conducted paraben safety reviews in 2010 (SCCS/1348/10), 2011 (SCCS/1446/11), and 2013 (SCCS/1514/13). The cumulative regulatory determination was implemented in two stages: Commission Regulation (EU) No 358/2014 (April 9, 2014) banned isopropylparaben, isobutylparaben, phenylparaben, benzylparaben, and pentylparaben from EU cosmetic products. Regulatory Commission Regulation (EU) No 1004/2014 (September 18, 2014) tightened propylparaben and butylparaben limits to 0.14% individual concentration and banned both in leave-on cosmetic products for the nappy area of children under 3 years old. Regulatory Both regulations took effect in April 2015 for new products and July 2015 for products already on the market.
Reproductive epidemiology — semen quality
Smith, Souter, Dimitriadis, Mínguez-Alarcón, Hauser and EARTH Study Team 2013 in Human Reproduction examined the association between urinary paraben concentrations and semen quality parameters in men attending a fertility clinic. Peer-reviewed The study reported associations between propylparaben and butylparaben metabolite concentrations and altered semen parameters, with the longer-chain parabens showing stronger associations than methylparaben — consistent with the in vitro estrogenicity ranking. The clinical significance of the observed effect sizes at typical population exposure remains an active research area.
CIR safety assessment
The Cosmetic Ingredient Review Amended Safety Assessment of Parabens conducted the US industry-funded systematic safety review and concluded that propylparaben at current use levels is safe in cosmetic formulations. Industry investigation CIR's position differs from the EU SCCS's tighter restrictions on propylparaben — the US regulatory and industry framework treats propylparaben as comparable to methylparaben for safety purposes, while EU framework treats them as separate safety tiers. The disagreement reflects different uncertainty-factor frameworks and different weighting of the endocrine literature.
Safety reviews and the contested epidemiology
Soni, Carabin and Burdock 2005 in Food and Chemical Toxicology reviewed paraben safety including propylparaben prior to the EU regulatory action. Peer-reviewed The Soni review concluded the parabens were safe at typical exposure levels — a conclusion that was subsequently revisited by EU SCCS in the 2010-2013 review cycle that produced the split regulatory framework. The Soni 2005 conclusion remains representative of one regulatory school of thought; the EU 2010-2014 conclusion represents the other. Both positions are documented in the literature and reflect different evidence weighting rather than fundamentally different empirical findings.
What helps reduce exposure
For products intended for children under 3, use EU-restriction-compliant formulations. The EU framework excludes propylparaben from leave-on cosmetic products applied to the nappy area of children under 3 — a useful shortcut even outside the EU since many global brands harmonize. Look for explicit "propylparaben-free" or "EU compliant" labeling on baby and toddler products, or check the ingredient list directly for propylparaben absence.
Read ingredient labels and choose paraben-free formulations where the alternative preservative is identified. "Paraben-free" without specifying the replacement preservative substitutes one unknown for another. Phenoxyethanol is the most common substitute and is covered separately on the phenoxyethanol atlas page.
For known paraben sensitivity (positive patch test): avoid the entire family. Cross-reactivity within the paraben family is common — patients sensitized to one paraben typically react to others on subsequent patch testing. The entire-family avoidance is the standard clinical recommendation.
Prioritize leave-on products for paraben-free choices. Same logic as for methylparaben: leave-on products produce the highest residence-time exposure. The marginal benefit of switching is largest in the leave-on category.
For cumulative paraben exposure (multiple products), simplify the routine. Households using many separate paraben-containing leave-on products receive additive paraben exposure across the products. Simplifying the routine reduces total exposure regardless of which specific paraben is in each product.
What does NOT help
- Generic "natural" or "clean beauty" labels without verifiable ingredient lists. Unregulated marketing terms. Independent ingredient disclosure or third-party certification (MADE SAFE, EWG Verified, COSMOS) is more reliable.
- Assuming "propylparaben-free" means paraben-free entirely. Methylparaben, ethylparaben, and other parabens may still be present. Check the full ingredient list rather than relying on the single-paraben-free claim.
- Overclaiming the breast cancer link. The Darbre 2004 finding documented propylparaben presence in tumor tissue but did not establish causality. The epidemiological literature has not demonstrated a causal link.
- Avoiding all preservatives. Water-containing cosmetic formulations require preservation against microbial contamination, which produces its own health risks.
Open research questions
- Cumulative paraben exposure — methyl + ethyl + propyl + butyl combined estrogenic load versus individual-compound assessment. The EU regulatory framework includes a total-parabens cap (0.8% combined), but the dose-response for combined exposure remains less precisely characterized than individual-compound dose-response. Speculation
- Differential metabolism between parabens — longer-chain parabens hydrolyze more slowly; the implications for tissue accumulation and longer biological half-life are documented in vitro but the residential exposure-pattern relevance is less precisely established. Inferred from established paraben pharmacokinetic differences
- Bedroom-specific propylparaben exposure pathways — pillowcase and bedding deposition has not been quantitatively studied at population scale specific to propylparaben. Speculation
- Replacement preservative safety profiles — as propylparaben-free formulations proliferate, the cumulative population exposure to phenoxyethanol and other replacements increases without parallel safety scrutiny. Speculation
Citations
- European Commission (2014). Commission Regulation (EU) No 358/2014 of 9 April 2014 amending Annexes II and V to Regulation (EC) No 1223/2009 on cosmetic products. Official Journal of the European Union, L 107/5. eur-lex.europa.eu Regulatory — isopropyl, isobutyl, phenyl, benzyl, pentylparaben bans
- European Commission (2014). Commission Regulation (EU) No 1004/2014 of 18 September 2014 amending Annex V to Regulation (EC) No 1223/2009. Official Journal of the European Union, L 282/5. eur-lex.europa.eu Regulatory — propyl/butylparaben 0.14% limit and nappy-area ban for children under 3
- Scientific Committee on Consumer Safety (2013). Opinion on Parabens, updated request for a scientific opinion on propyl- and butylparaben (SCCS/1514/13). European Commission. health.ec.europa.eu Regulatory
- Darbre PD, Aljarrah A, Miller WR, Coldham NG, Sauer MJ, Pope GS (2004). Concentrations of parabens in human breast tumours. Journal of Applied Toxicology, 24(1):5-13. DOI 10.1002/jat.958 Peer-reviewed
- Routledge EJ, Parker J, Odum J, Ashby J, Sumpter JP (1998). Some alkyl hydroxy benzoate preservatives (parabens) are estrogenic. Toxicology and Applied Pharmacology, 153(1):12-19. DOI 10.1006/taap.1998.8544 Peer-reviewed — foundational chain-length estrogenicity demonstration
- Smith KW, Souter I, Dimitriadis I, Mínguez-Alarcón L, Hauser R; EARTH Study Team (2013). Urinary paraben concentrations and ovarian aging among women from a fertility center. Environmental Health Perspectives, 121(11-12):1299-1305. DOI 10.1289/ehp.1205350 Peer-reviewed
- Boberg J, Taxvig C, Christiansen S, Hass U (2010). Possible endocrine disrupting effects of parabens and their metabolites. Reproductive Toxicology, 30(2):301-312. DOI 10.1016/j.reprotox.2010.06.012 Peer-reviewed
- Soni MG, Carabin IG, Burdock GA (2005). Safety assessment of esters of p-hydroxybenzoic acid (parabens). Food and Chemical Toxicology, 43(7):985-1015. DOI 10.1016/j.fct.2005.05.011 Peer-reviewed
- Cosmetic Ingredient Review. Amended Safety Assessment of Parabens as Used in Cosmetics. cir-safety.org Industry investigation — formal industry safety review
- US Centers for Disease Control and Prevention. National Report on Human Exposure to Environmental Chemicals — NHANES paraben biomonitoring. cdc.gov/exposurereport Regulatory — population-scale biomonitoring
Frequently asked questions
Is propylparaben safe?
EU SCCS reviews concluded propylparaben is safe at up to 0.14% individual concentration in cosmetics — substantially lower than methylparaben's 0.4% limit, reflecting the stronger estrogenic activity of the longer-chain paraben. Propylparaben is banned in EU leave-on cosmetic products for the nappy area of children under three (Commission Regulation 358/2014). The US FDA continues to permit propylparaben in cosmetics under the broader cosmetic regulation framework without specific concentration limits. Whether propylparaben is "safe" depends on the exposure scenario; the EU regulatory framework treats it as moderately restricted rather than banned.
Why was propylparaben restricted in Europe?
The EU Scientific Committee on Consumer Safety conducted multiple paraben safety reviews in 2010, 2011, and 2013. The conclusions split the paraben family into safety tiers based on chain length: methylparaben and ethylparaben were assessed as safe at higher use levels; propylparaben and butylparaben were assessed as showing stronger endocrine activity warranting tighter concentration limits; isopropylparaben, isobutylparaben, phenylparaben, benzylparaben, and pentylparaben were assessed as having inadequate safety data and were banned. The regulatory split reflects the in vitro estrogenicity data showing receptor binding affinity increases with paraben chain length.
Is propylparaben stronger than methylparaben?
Yes — approximately 10× stronger in published in vitro estrogen receptor binding assays. The chain-length-versus-estrogenicity relationship is consistent across the paraben family: methylparaben (C1 ester) is the weakest, ethylparaben (C2) is intermediate, propylparaben (C3) shows further increase, and butylparaben (C4) is the strongest of the commonly-used parabens. Both propylparaben and methylparaben remain approximately three to four orders of magnitude weaker than 17β-estradiol in standard assays, but the chain-length effect is the basis for differential regulatory treatment within the family.
Is propylparaben banned in baby products?
In the EU, propylparaben (and butylparaben) is banned in leave-on cosmetic products applied to the nappy area of children under three years old, per Commission Regulation 358/2014, in effect since April 2015. The ban is product-category-specific: rinse-off products and products not applied to the nappy area are still permitted at the 0.14% concentration limit. Many global brands have harmonized their formulations to the EU restriction even outside the EU, but US-only or imported products may still contain propylparaben in baby formulations. Check ingredient labels.
What is E216?
E216 is the EU food-additive labeling designation for propylparaben (sodium propyl 4-hydroxybenzoate). Propylparaben was historically used as a food preservative under the E216 label, but the EU banned propylparaben in food applications in 2006 following the European Food Safety Authority's 2004 opinion that established a tolerable daily intake covering only the shorter-chain parabens. The current EU food preservative parabens are methylparaben (E218) and ethylparaben (E214). The propylparaben food ban predates the 2014 cosmetics restrictions and is unrelated to the breast cancer literature — it was driven by the same in vitro estrogenicity dose-response that subsequently drove the cosmetics restrictions.
Does propylparaben cause breast cancer?
The evidence is contested, with the same honest framing as for methylparaben. Darbre and colleagues' 2004 study detected propylparaben in human breast tumor tissue alongside methylparaben, with propylparaben present at the highest mean concentration of any paraben measured. The 2004 finding did not establish causality; the subsequent epidemiological literature has not demonstrated a causal link between paraben exposure and breast cancer incidence. Stating the parabens-cause-breast-cancer claim as established science is overclaim; the honest framing is that propylparaben specifically has documented in vitro estrogenic activity and measurable human breast tissue accumulation, with the causal step from those observations to clinical cancer outcomes not established by current evidence.
What's the difference between propylparaben and butylparaben?
Both are longer-chain parabens — propyl is the C3 ester, butyl is the C4 ester. Butylparaben shows the strongest in vitro estrogenic activity of the commonly-used parabens. Both have the same EU cosmetics concentration limit (0.14%), the same EU leave-on ban for children under 3 nappy-area products, and similar overall toxicological profiles. The regulatory treatment is parallel because the chemistry is parallel; the in vitro estrogenicity ranking is propyl < butyl, but the dose-response difference is small enough that both fall into the same regulatory tier rather than being separated like methyl was separated from propyl.
Related compounds
Embr Sleep is a sleep environment company researching the chemistry of the bedroom. See the methodology page for how this Atlas tags claims by evidence strength. For broader context on personal care chemistry, see non-toxic bedroom.
Last reviewed 2026-05-25. If you find a factual error, contact us.